Advancements in targeted therapies based on the egfr, and kras genetic mutations in lung cancer

HIGHLIGHTS

• What: This study shows the importance of the comprehensive view at treating certain diseases, that even though personalized medicine could work for these varied responses, there are still factors that should be considered, such as the cost, and applicability, while allowing the audience to look at more ways to improve this solution, such as drug repurposing. The analysis focused primarily on EGFR and KRAS mutations, in one type of lung cancer, NSCLC leaving a handful of other significant mutations, such as the ALK mutation, and TP53 mutations. The aim of this research is to engage the audience . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.